Search clinical trials for: safety tolerability and immunogenicity of two different doses of DLX105 applied intra-dermally into

Total 490319 results

Delenex Therapeutics AG

Completed

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris (2011-00500-15)

Mild-to-moderate Psoriasis Vulgaris

Austria, Germany
DelArrivo, Inc.

Completed

A Study of DLX105-DMP in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
ESBATech AG

Completed

Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee

Osteoarthritis

Germany, Switzerland
Delenex Therapeutics AG

Completed

Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease

Fistulizing Crohn's Disease

Switzerland
Delenex Therapeutics AG

Completed

Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients

Psoriasis Vulgaris

Germany, Austria
Chiesi Farmaceutici S.p.A.
SGS S.A.

Recruiting

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Asthma

Belgium
Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

United States
Jiangsu Province Centers for Disease Control and...
Academy of Military Medical Sciences，Academy of Military Sciences，PLA; ZHONGYIANKE... and other collaborators

Recruiting

Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)

COVID-19

China
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

COVID-19

China
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months

Influenza

Guatemala
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

Pre-pandemic Influenza Vaccine

Czech Republic
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
Medical University of Vienna

Completed

A Prospective Randomized Double-Blinded Placebo Controlled, Explorative Phase I Trial to Investigate the Safety and Tolerability of Two Different Doses of Topically Administered APOSEC™ in Healthy Male Subjects With Artificial Dermal Wounds

Healthy | Artificial Dermal Wound

Austria
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Meningococcal Disease

United Kingdom
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years

Prophylaxis of Avian Influenza

Finland
Noscira SA
i3 Research

Completed

Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy (Tauros)

Progressive Supranuclear Palsy

United States, Germany, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus

Renal Transplantation

Switzerland
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

Influenza

Poland
AstraZeneca
AstraZeneca K.K.

Recruiting

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia (PURSUIT)

Dyslipidemia

Denmark, Hungary, Spain, United States, Japan, Czechia, Slovakia, Canada
ViiV Healthcare

Recruiting

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

Influenza

United States
argenx

Recruiting

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Healthy Volunteers

Netherlands
Green Cross Wellbeing

Recruiting

Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Chronic Liver Disease

Korea, Republic of
Huashan Hospital

Recruiting

A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine

COVID-19 | Vaccine Reaction

China
ViGenCell Inc.

Not yet recruiting

A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)

Graft Versus Host Disease
Bazell Pharma AG

Not yet recruiting

Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE) (BESIDE)

Eosinophilic Esophagitis
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Zhejiang Provincial Center for Disease Control and Prevention

Recruiting

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV

COVID-19

China
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Respiratory Syncytial Virus (RSV)

United States
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

Covid19

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Schistosomiasis

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

H3N2 Influenza

United States
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
Minervax ApS
Iqvia Pty Ltd

Active, not recruiting

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

Group B Streptococcal Infections

Belgium
Xinnate AB
Region Skane

Completed

Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.

Blister | Epidermolysis Bullosa | Wound of Skin | Varicose Ulcer of Lower Limb

Sweden
Enlivex Therapeutics Ltd.
Cato Research; Accelsiors CRO & Consultancy Services

Active, not recruiting

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Sepsis | Intraabdominal Infections | Cholecystitis, Acute | Urinary Tract Infections | Community-acquired Pneumonia | Cholangitis Acute

Netherlands, Israel, France, Belgium, Spain
Vivoryon Therapeutics N.V.
Amsterdam UMC, location VUmc; Nordic Bioscience A/S

Completed

A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD (VIVIAD)

Early Alzheimers Disease | Mild Cognitive Impairment Due to AD

Netherlands, Spain, Denmark, Germany, Poland
GlaxoSmithKline

Completed

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Sweden, Korea, Republic of, Brazil, Mexico, Canada, Italy, France, Czechia, Estonia, Hong Kong, United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

United States
Ospedale Policlinico San Martino
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency (4CMenB)

Acquired Immunodeficiency

Italy
Hualan Biological Bacterin Co. Ltd.
Henan Center for Disease Control and Prevention

Completed

To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell) (rabies)

Rabies Human

China
Cinclus Pharma AG
Parexel

Completed

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Erosive Esophagitis

Poland, Bulgaria, Serbia, Georgia, United States, Czechia, Hungary, Ukraine
Institute of Medical Biology, Chinese Academy of...
Guangxi Center for Disease Control and Prevention

Completed

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

Poliomyelitis

China

3

Subscribe